The test enabled stratification of breast cancer patients into eligible and non-eligible for Roche/Genentech’s monoclonal antibody therapeutic Herceptin® (trastuzumab) based on the prognostic biomarker HER2/neu presented in 20–30 % of breast cancer patients [62, 63]. The gene discussed is ERBB2; the disease is breast carcinoma.